The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis. RESULTS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be different types of renal cancer characterized by specific genetic alterations, with type 2 further classified into three individual subgroups on the basis of molecular differences associated with patient survival. Type 1 tumors were associated with MET alterations, whereas type 2 tumors were characterized by CDKN2A silencing, SETD2 mutations, TFE3 fusions, and increased expression of the NRF2-antioxidant response element (ARE) pathway. A CpG island methylator phenotype (CIMP) was observed in a distinct subgroup of type 2 papillary renal-cell carcinomas that was characterized by poor survival and mutation of the gene encoding fumarate hydratase (FH). CONCLUSIONS: Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“another possible mechanism by which D-2-HG drives tumorigenesis is through the promotion of genetic instability, predisposing cells to oncogenic transformation103.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“Genomic studies have established that somatic mutations in IDH1 and IDH2 are perhaps the first genetic events to occur during tumorigenesis in human glioma and AML, and appear to initiate pathogenesis by a common mechanism103,115-117.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
In the citing paper
“The most commonly occurring cancers thought to arise from mutant IDH1/2 (mIDH1/2) include glioma, cartilaginous tumours, AML, angioimmunoblastic T cell lymphoma (AITL) and intrahepatic cholangiocarcinoma (ICC).”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [103]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Self-citationComprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Flagged first, then by citations
1 of the 42 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Delahunt B, 1997, Mod Pathol, 10, 537
- Schmidt LS, 1998, Cancer Res, 58, 1719
Cited by
Sorted by citations
Items 601–700 of 1,000
Genomic alterations and diagnosis of renal cancer
Zhang, X., Bolck, H. A., Rupp, N. J., & Moch, H. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03700-9 · Cited by 15
Deng, J., Tu, S., Li, L., Li, G., & Zhang, Y. (2024) · Cancer Reports · doi:10.1002/cnr2.2116 · Cited by 15
Contemporary review of papillary renal cell carcinoma—current state and future directions
Castillo, V. F., Trpkov, K., & Saleeb, R. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03865-x · Cited by 15
Gao, Y., Fan, S., Sun, X., Li, J., Dai, Y., Li, H., Ma, H., Xu, Y., & Lv, L. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07752-4 · Cited by 16
Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis
Modi, P. K., & Singer, E. A. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.43 · Cited by 15
Park, J. H., Lee, C., Chang, M. S., Kim, K., Choi, S., Lee, H., Lee, H., & Moon, K. C. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.010 · Cited by 15
Ziogas, D. E., Kyrochristos, I. D., & Roukos, D. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.008 · Cited by 15
Update on the Biology and Management of Renal Cell Carcinoma
Dutcher, J. P. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000918 · Cited by 15
Hepatocyte gene expression and DNA methylation as ancestry-dependent mechanisms in African Americans
Park, C. S., De, T., Xu, Y., Zhong, Y., Smithberger, E., Alarcon, C., Gamazon, E. R., & Perera, M. A. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0102-y · Cited by 15
Rao, H., Li, X., Liu, M., Liu, J., Li, X., Xu, J., Li, L., & Gao, W. (2020) · Oncogene · doi:10.1038/s41388-020-1247-y · Cited by 15
Simon, A. G., Tolkach, Y., Esser, L. K., Ellinger, J., Stöhr, C., Ritter, M., Wach, S., Taubert, H. W., Stephan, C., Hartmann, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75258-4 · Cited by 15
Zhou, X., Qiu, S., Jin, D., Jin, K., Zheng, X., Yang, L., & Wei, Q. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.569884 · Cited by 15
Ayton, S. G., Pavlicová, M., Robles‐Espinoza, C. D., Tamez‐Peña, J. G., & Treviño, V. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.09.006 · Cited by 15
A genomic mutation spectrum of collecting duct carcinoma in the Chinese population
Zhang, H., Lu, X., Huang, G., Hua, M., Zhang, W., Wang, T., Huang, L., Wang, Z., Chen, Q., Li, J., et al. (2022) · BMC Medical Genomics · doi:10.1186/s12920-021-01143-2 · Cited by 15
Erdem, S., Umberto Capitanio, A., Campi, R., Mir, M. C., Roussel, E., Pavan, N., Kara, Ö., Klatte, T., KRIEGMAIR, M. C., Değirmenci, E., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.01.006 · Cited by 15
Ueno, D., Vasquez, J. C., Sule, A. D., Liang, J., Doorn, J. V., Sundaram, R. K., Friedman, S., Caliliw, R., Ohtake, S., Bao, X., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28273 · Cited by 15
Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer
Vaishampayan, U. N. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0521-5 · Cited by 15
Kaldany, A., Paulucci, D. J., Kannappan, M., Beksac, A. T., Anastos, H., Okhawere, K. E., Sfakianos, J. P., & Badani, K. K. (2019) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.05.008 · Cited by 15
The Labyrinth of Renal Cell Carcinoma
Manini, C., & Lopez, J. I. (2020) · Cancers · doi:10.3390/cancers12020521 · Cited by 15
The complex role of NRF2 in cancer: A genomic view
Praslicka, B. J., Kerins, M. J., & Ooi, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.003 · Cited by 14
Molecular and therapeutic landscape of non-clear cell renal carcinoma
Nepali, P. R., Eraky, A., Okhawere, K. E., Dogra, N., Mehrazin, R., Badani, K. K., & Kyprianou, N. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01056-0 · Cited by 15
Yang, J., Miao, D., Li, X., Zhao, C., Tan, D., Wu, S., Lu, F., Shi, J., Lv, Q., Ruan, H., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1664292 · Cited by 15
Papillary renal neoplasm with reverse polarity—a comparative study with CCPRCC, OPRCC, and PRCC1
Wang, T., Ding, X., Huang, X., Ye, J., Li, H., Cao, S., Gao, Y., Ma, X., Huang, Q., & Wang, B. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.07.010 · Cited by 14
Xu, P., Zhang, S., Cao, B., Huang, J., Li, Y., Cheng, J., Lin, W., Cheng, J. J., Chen, W., Zhu, Y., et al. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02824-7 · Cited by 14
Artificial Intelligence in Bladder Cancer Diagnosis: Current Applications and Future Perspectives
Rossin, G., Zorzi, F., Ongaro, L., Piasentin, A., Vedovo, F., Liguori, G., Zucchi, A., Simonato, A., Bartoletti, R., Trombetta, C. S., et al. (2023) · BioMedInformatics · doi:10.3390/biomedinformatics3010008 · Cited by 15
Ullah, A., Yasinzai, A. Q. K., Daino, N., Tareen, B., Jogezai, Z. H., Sadia, H., Jamil, N., Baloch, G., Karim, A., Badini, K., et al. (2023) · Journal of Kidney Cancer and VHL · doi:10.15586/jkcvhl.v10i4.294 · Cited by 14
Massari, F., Mollica, V., Fiala, O., Giorgi, U. D., Kucharz, J., Vitale, M. G., Molina‐Cerrillo, J., Facchini, G., Seront, E., Lenci, E., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.03.011 · Cited by 14
Manley, B. J., & Hsieh, J. J.-D. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.07.30 · Cited by 14
ALK-rearranged renal cell carcinomas in Polish population
Gorczyński, A., Czapiewski, P., Korwat, A., Budyńko, Ł., Prełowska, M. K., Okoń, K., & Biernat, W. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152669 · Cited by 14
Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments
Schmidt, A. L., Siefker-Radtke, A. O., McConkey, D. J., & McGregor, B. A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279905 · Cited by 14
Cellular State Transformations Using Deep Learning for Precision Medicine Applications
Targonski, C., Bender, M. R., Shealy, B. T., Husain, B., Paseman, B., Smith, M. C., & Feltus, F. A. (2020) · Patterns · doi:10.1016/j.patter.2020.100087 · Cited by 14
Lue, H.-W., Derrick, D. S., Rao, S. A. M., Gaest, A. V., Cheng, L. C., Podolak, J., Lawson, S., Xue, C., Garg, D., White, R. E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100267 · Cited by 14
Wang, X., Song, G., Jiang, H., Zheng, L., Pang, P., & Xu, J. (2021) · Abdominal Radiology · doi:10.1007/s00261-021-03090-z · Cited by 14
Albiges, L. K., Heng, D. Y. C., Lee, J., Walker, S. R., Mellemgaard, A., Ottesen, L. H., Frigault, M. M., L’Hernault, A., Wessen, J., Choueiri, T. K., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.021 · Cited by 14
HIRA loss transforms FH -deficient cells
Valcárcel-Jiménez, L., Rogerson, C., Yong, C., Schmidt, C., Yang, M. H., Cremades-Rodelgo, M., Harle, V. J., Offord, V., Wong, K., Mora, A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq8297 · Cited by 14
McClure, M. B., Kogure, Y., Ansari‐Pour, N., Saito, Y., Chao, H., Shepherd, J. H., Tabata, M., Olopade, O. I., Wedge, D. C., Hoadley, K. A., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0073 · Cited by 14
Andeen, N. K., Qu, X., Antic, T., Tykodi, S. S., Fang, M., & Tretiakova, M. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0104-oa · Cited by 14
Li, J., Tan, G., Cai, Y., Liu, R., Xiong, X., Gu, B., He, W., Liu, B., Ren, Q., Wu, J., et al. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114620 · Cited by 14
Wang, H., Chen, X., Zhao, J., Kang, M., Dong, R., Wang, K., & Qu, Y. (2020) · Medical Science Monitor · doi:10.12659/msm.921859 · Cited by 14
Proteomic signatures of clear cell renal cell carcinoma
Creighton, C. J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0233-5 · Cited by 14
Renal cell carcinoma: molecular characterization and evolving treatment paradigms
Ball, M. W., Singer, E. A., & Srinivasan, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000364 · Cited by 13
Li, W., Wang, B., Dong, S., Xu, C., Song, Y. S., Qiao, X., Xu, X., Huang, M., & Yin, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.851552 · Cited by 13
Karmokar, P. F., & Moniri, N. H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02967-x · Cited by 13
Kidney cancer: Links between hereditary syndromes and sporadic tumorigenesis
Alchoueiry, M., Cornejo, K. M., & Henske, E. P. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.11.002 · Cited by 13
Habeeb, M., Arsey, S., You, H. W., Kumbhar, S. T., Aher, K. B., Bhavar, G. B., & Vengateswaran, H. T. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105983 · Cited by 13
Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark
Wang, L., Pattnaik, A., Sahoo, S. S., Stone, E., Zhuang, Y., Benton, A., Tajmul, M., Chakravorty, S., Dhawan, D., Nguyen, M. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51859-9 · Cited by 13
French AFU Cancer Committee Guidelines – Update 2024–2026: Management of kidney cancer
Bigot, P., Boissier, R., Khene, Z., Albiges, L. K., Bernhard, J., Corréas, J.-M., Vergie, S. D., Doumerc, N., Ferragu, M., Ingels, A., et al. (2024) · The French Journal of Urology · doi:10.1016/j.fjurol.2024.102735 · Cited by 13
Lee, H. J., Shokri, F., & Tretiakova, M. (2025) · Human Pathology · doi:10.1016/j.humpath.2025.105862 · Cited by 13
Rochigneux, P., Piana, J. T., Laibe, S., Brunelle, S., Salem, N., Escudier, B. J., Vassal, G., & Gravis, G. (2018) · BMC Cancer · doi:10.1186/s12885-018-5049-3 · Cited by 13
Cullin-Ring ubiquitin ligases in kidney health and disease
Cornelius, R. J., Ferdaus, M. Z., Nelson, J. W., & McCormick, J. A. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000527 · Cited by 13
Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Nassar, A. H., Hamieh, L., Gray, K. P., Thorner, A. R., Fay, A. P., Lasseter, K. D., Alaiwi, S. A., Nuzzo, P. V., Flippot, R., Krajewski, K. M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0642 · Cited by 13
A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma
Patel, H. V., Srivastava, A., Srinivasan, R., & Singer, E. A. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000721 · Cited by 13
Saleeb, R., Brimo, F., Gao, Y., Boulos, C., Kim, S. S., Bashir, S. M. A., Husain, A., Rotondo, F., Beharry, V., Bjarnason, G. A., et al. (2021) · Human Pathology · doi:10.1016/j.humpath.2021.12.006 · Cited by 13
Xu, H., Li, W., Zhu, C., Cheng, N., Li, X., Hao, F., Zhu, J., Huang, L., Wang, R., Wang, L., et al. (2022) · The Journal of Pathology · doi:10.1002/path.5869 · Cited by 13
Zschäbitz, S., Erlmeier, F., Stöhr, C., Herrmann, E., Polifka, I., Agaimy, A., Trojan, L., Ströbel, P., Becker, F. O., Wülfing, C., et al. (2022) · Journal of Cancer · doi:10.7150/jca.63509 · Cited by 13
Renal oncocytoma: a challenging diagnosis
Mirkheshti, N., Farrukh, N., Legesse, T. B., Rowe, S. P., Gordetsky, J., & Hussain, A. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000829 · Cited by 13
Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma
Pahwa, R., Dubhashi, J., Singh, A. N., Jailwala, P., Lobanov, A. V., Thomas, C. J., Ceribelli, M., Wilson, K. M., Ricketts, C. J., Vocke, C. D., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02416-z · Cited by 13
Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1
Hong, S. H., Hwang, H. J., Son, D. H., Kim, E. S., Park, S. Y., & Yoon, Y. E. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13579 · Cited by 13
FOXA2 controls the anti-oxidant response in FH-deficient cells
Rogerson, C., Sciacovelli, M., Maddalena, L. A., Pouikli, A., Segarra‐Mondejar, M., Valcárcel-Jiménez, L., Schmidt, C., Yang, M. H., Ivanova, E., Kent, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112751 · Cited by 13
Treatment of Metastatic Renal Cell Carcinoma
Richter, I., & Dvořák, J. (2018) · Klinicka onkologie · doi:10.14735/amko2018110 · Cited by 13
Recognizing Hereditary Renal Cancers Through the Microscope
Peng, Y., & Chen, Y. (2018) · Surgical pathology clinics · doi:10.1016/j.path.2018.07.010 · Cited by 13
Crona, J., Backman, S., Welin, S., Taïeb, D., Hellman, P., Stalberg, P. L. H., Skogseid, B. M., & Pacák, K. (2018) · Cancers · doi:10.3390/cancers10120518 · Cited by 13
Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management
Silagy, A. W., Sánchez, A., Manley, B. J., Bensalah, K., Bex, A., Karam, J. A., Ljungberg, B., Shuch, B. M., & Hakimi, A. A. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.04.011 · Cited by 13
Ren, W., Gao, X., Zhang, X., Hu, J., Li, H., & Zu, X.-Y. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02181-0 · Cited by 13
Tumors of the kidney. The new 2016 WHO classification of tumors of the genitourinary system
Bezhanova, S. D. (2017) · Russian Journal of Archive of Pathology · doi:10.17116/patol201779248-52 · Cited by 13
Luo, Q., Cui, M., Deng, Q., & Liu, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10138 · Cited by 13
Sourbier, C., Ricketts, C. J., Liao, P., Matsumoto, S., Wei, D., Lang, M., Railkar, R. S., Yang, Y., Wei, M.-H., Agarwal, P. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55003-2 · Cited by 13
D’Angelo, A., Bagby, S., Pierro, G. D., Chirra, M., Nobili, S., Mini, E., Villari, D., & Roviello, G. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102921 · Cited by 13
Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma
Zhu, S., Chen, J., & Zeng, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041526 · Cited by 13
Cao, H., Jia, C., Li, Z., Yang, H., Fang, R., Zhang, Y., & Cui, Y. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02587-w · Cited by 12
MiT family translocation carcinomas of the kidney and related entities
Argani, P. (2025) · Histopathology · doi:10.1111/his.15560 · Cited by 12
Dai, C., Huang, J., Li, Y., Zhang, S., Tan, Q., Hou, J., Tang, Q., Hu, X., Guo, J., Zeng, M., et al. (2020) · European Radiology · doi:10.1007/s00330-020-07456-7 · Cited by 12
Sweeney, P. L., Jang, A., Halat, S. K., Pal, S. K., & Barata, P. C. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100639 · Cited by 12
Metastasis in renal cell carcinoma: Biology and treatment
Kanwal, R. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100094 · Cited by 12
Li, J., Wilkerson, M. L., Deng, F., & Liu, H. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0493-ra · Cited by 12
Stransky, L. A., Gao, W., Schmidt, L. S., Bi, K., Ricketts, C. J., Ramesh, V., James, A. E., Difilippantonio, S., Ileva, L. V., Kalen, J. D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408549121 · Cited by 12
SMMILe enables accurate spatial quantification in digital pathology using multiple-instance learning
Gao, Z., Mao, A., Dong, Y., Clayton, H., Wu, J., Liu, J., Wang, C., He, K., Gong, T., Li, C., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-01060-8 · Cited by 13
Surveillance following surgery for nonmetastatic renal cell carcinoma
Richards, K. A., & Abel, E. J. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000308 · Cited by 12
Photoinducible Oncometabolite Detection
Kulkarni, R. A., Briney, C. A., Crooks, D. R., Bergholtz, S. E., Mushti, C., Lockett, S., Lane, A. N., Fan, T. W. ‐., Swenson, R. E., Linehan, W. M., et al. (2018) · ChemBioChem · doi:10.1002/cbic.201800651 · Cited by 12
MDM2 amplification and immunohistochemical expression in sarcomatoid renal cell carcinoma
Suster, D. I., Ronen, S., Peterson, J. F., Mackinnon, A. C., Hes, O., Suster, S. M., & Lin, D. I. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.02.004 · Cited by 12
Yang, M. G., Hlady, R. A., Zhou, D., Ho, T. H., & Robertson, K. D. (2019) · Cancer Medicine · doi:10.1002/cam4.2402 · Cited by 12
Contemporary Renal Tumor Categorization With Biomarker and Translational Updates: A Practical Review
Taylor, A. S., Spratt, D. E., Dhanasekaran, S. M., & Mehra, R. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0442-ra · Cited by 12
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma
Gan, C. L., Dudani, S., & Heng, D. Y. C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000468 · Cited by 12
Clinicopathologic features of TDO2 overexpression in renal cell carcinoma
Phạm, Q. T., Taniyama, D., Sekino, Y., Akabane, S., Babasaki, T., Kobayashi, G., Sakamoto, N., Sentani, K., Oue, N., & Yasui, W. (2021) · BMC Cancer · doi:10.1186/s12885-021-08477-1 · Cited by 12
AS-CMC: a pan-cancer database of alternative splicing for molecular classification of cancer
Park, J., Lee, J., Lee, M., & Chung, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-25584-6 · Cited by 12
Bovine Colostrum Treatment of Specific Cancer Types: Current Evidence and Future Opportunities
Alsayed, A. R., Hasoun, L., Khader, H. A., Basheti, I. A., & Permana, A. D. (2022) · Molecules · doi:10.3390/molecules27248641 · Cited by 12
Riveros, C. A., Ranganathan, S., Xu, J., Chang, C. R., Kaushik, D., Morgan, M. S. C., Miles, B. J., Muhammad, T., Anis, M., Aghazadeh, M. A., et al. (2023) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.11.022 · Cited by 12
Takamatsu, D., Kohashi, K., Kiyozawa, D., Kinoshita, F., Ieiri, K., Baba, M., Eto, M., & Oda, Y. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154313 · Cited by 12
Molecular differences in renal cell carcinoma between males and females
Pallauf, M., Ged, Y. M. A., & Singla, N. (2023) · World Journal of Urology · doi:10.1007/s00345-023-04347-6 · Cited by 12
Castillo, V. F., Trpkov, K., van der Kwast, T., Rotondo, F., Hamdani, M., & Saleeb, R. (2024) · Pathology International · doi:10.1111/pin.13417 · Cited by 12
Wen, X., Hou, J., Qi, T., Cheng, X., Liao, G., Fang, S., Song, X., Qiu, L., & Wei, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1427475 · Cited by 15
Therapeutic Strategies for Hereditary Kidney Cancer
Sidana, A., & Srinivasan, R. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0537-6 · Cited by 12
Weiten, R., Müller, T., Schmidt, D. H., Steiner, S., Kristiansen, G., Müller, S. C., Ellinger, J., & Syring, I. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170757 · Cited by 12
Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update
Cox, R. M., Magi‐Galluzzi, C., & McKenney, J. K. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000205 · Cited by 12
Nunno, V. D., Mollica, V., Brunelli, M., Gatto, L., Schiavina, R., Fiorentino, M., Santoni, M., Montironi, R., Caliò, A., Eccher, A., et al. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00414-0 · Cited by 12
Mikhaylenko, D. S., Klimov, A., Matveev, V. B., Ивановна, С. С., Strelnikov, V. V., Zaletaev, D. V., Lyubchenko, L. N., Alekseev, B. Y., & Nemtsova, M. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01566 · Cited by 12
A novel CpG-methylation-based nomogram predicts survival in colorectal cancer
Wang, X., Wang, D., Liu, J., Feng, M., & Wu, X.-Z. (2020) · Epigenetics · doi:10.1080/15592294.2020.1762368 · Cited by 12
Malouf, G. G., Flippot, R., & Khayat, D. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011809 · Cited by 12
Pompas-Veganzones, N., Sandonis, V., Perez-Lanzac, A., Beltran, M., Beardo, P., Juárez, Á., Vazquez, F., Cozar, J. M., Alvarez-Ossorio, J. L., & Sänchez‐Carbayo, M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5267-8 · Cited by 12
A DFT study of hydrogen storage of a novel 2D m-BC nanosheet
Miao, Z., Ding, J., Ge, Y., Yang, Z., Wang, Y., & Bi, L. (2023) · Materials Science in Semiconductor Processing · doi:10.1016/j.mssp.2023.107636 · Cited by 11
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- The Cancer Genome Atlas Research Network
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-14
- Volume
- 374
- Issue
- 2
- Pages
- 135-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4775252
- OpenAlex
- W2111867681
- Cited by
- 1,336
- References
- 42
- Citations by year
- 2026: 60 · 2025: 100 · 2024: 95 · 2023: 130 · 2022: 135 · 2021: 159 · 2020: 153 · 2019: 151 · 2018: 128 · 2017: 126 · 2016: 96
- FWCI
- 92.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (K24CA172355, U24CA143882, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA199461, U24CA143883, U24CA143845, U24CA180951, U24CA143867, R01CA169172, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA015083, P30CA016672, P30CA016056, P30CA016086)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- papillary renal cell carcinoma, type 2 papillary renal cell carcinoma, MET alterations, SETD2 mutation, TFE3 fusion, Nrf2/ARE pathway, CpG island methylator phenotype, tumor subtypes, prognosis, molecular heterogeneity
- MeSH terms
- Carcinoma, Papillary, Humans, Kidney Neoplasms, Mutation, Phenotype, RNA, Messenger, RNA, Neoplasm, Signal Transduction, Sequence Analysis, RNA, CpG Islands, DNA Methylation, Proto-Oncogene Proteins c-met, MicroRNAs, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
